FREMONT, Calif. and BALTIMORE, Oct. 12 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. announces that Carol Berry, Head of Corporate Marketing/North American Sales, will participate in a panel discussion during the American Association for Clinical Chemistry’s (AACC) conference entitled “Proteomics: Opportunities for Diagnostics, Pharmaceuticals, and the Clinical Laboratory.” The conference will focus on the future of diagnostic medicine, biomarker discovery and the role of proteomics. Ms. Berry will participate on the panel entitled “Cancer Diagnostic Technologies: From Bench to the Bedside” on Saturday, October 14, 2006.
Ciphergen also is hosting an industry workshop entitled “Delivering Proteomics to the Clinic” on Thursday, October 12, 2006 from 3:00 p.m.- 5:00 p.m. before the start of the conference. Leading experts in proteomics and diagnostic development will present information on the latest advancements in assay development, biomarker validation, technology enhancements and issues surrounding the clinical laboratory industry regulatory environment. The Saturday commercial program will feature executives from biotech and diagnostic companies discussing the barriers, greatest areas of opportunity and potential contributions of proteomics to clinical diagnostics.
“Ciphergen has extensive experience in all aspects of diagnostic development, from biomarker discovery and validation to clinical trial design and commercialization,” said Gail S. Page, President and CEO of Ciphergen Biosystems. “The AACC panel and industry workshop provides Ciphergen with the opportunity to showcase its expertise bringing proteomic-based diagnostic tests to the marketplace.”
The AACC conference takes place October 13-14, 2006 at the Hyatt Regency in Baltimore, MD.
About Ciphergen
Ciphergen Biosystems, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Ciphergen, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology, cardiology and women’s health with an initial focus in ovarian cancer. Based in Fremont, California, more information about Ciphergen can be found on the Web at http://www.ciphergen.com .
Ciphergen has an advanced diagnostic program in ovarian cancer and has developed a panel of biomarkers that provides risk stratification information for ovarian cancer based on a series of studies involving over 2,000 clinical samples from more than five sites. Ciphergen has an alliance with Quest Diagnostics to commercialize this marker set under the analyte specific reagent, or ASR, regulations. Ciphergen is simultaneously undertaking a prospective clinical trial to support submission to the FDA for approval as an in vitro diagnostic test.
NOTE: Ciphergen, ProteinChip and Biomarker Discovery Center are registered trademarks of Ciphergen Biosystems, Inc.
Ciphergen Biosystems, Inc.
CONTACT: Sue Carruthers, Investor Relations of Ciphergen Biosystems, Inc.,+1-510-505-2233; or media, Andrea Campbell of WeissComm Partners,+1-281-360-7239, for Ciphergen Biosystems, Inc.
Web site: http://www.ciphergen.com/
